Literature DB >> 2979233

Pharmacological manipulation of adynamic ileus: controlled randomized double-blind study of ceruletide on intestinal motor activity after elective abdominal surgery.

S A Sadek1, C Cranford, C Eriksen, M Walker, C Campbell, P R Baker, R A Wood, A Cuschieri.   

Abstract

In a double-blind placebo-controlled trial of patients undergoing elective abdominal surgery (n = 91), a single intravenous infusion of ceruletide (2.5 ng kg-1 min-1 for 1 hour) resulted in audible bowel sounds in 42/47 patients as opposed to 30/44 receiving placebo (P less than 0.025). Excessive bowel sounds were noted in 16 patients in the ceruletide group and four receiving placebo (P less than 0.01). Significantly more patients (P less than 0.01) in the ceruletide group (22/45 versus 9/44) passed flatus per rectum between the second and third post-operative day. Ceruletide infusion was accompanied by a significant increase in the incidence of nausea and vomiting (P less than 0.005, P less than 0.0025) but these side effects were short-lived. These results indicate that ceruletide is likely to be a useful therapeutic agent for acute intestinal adynamic motility disorders.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2979233     DOI: 10.1111/j.1365-2036.1988.tb00671.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  3 in total

Review 1.  Postoperative ileus: progress towards effective management.

Authors:  Kathrine Holte; Henrik Kehlet
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Review of the pathophysiology and management of postoperative ileus.

Authors:  Peter Mattei; John L Rombeau
Journal:  World J Surg       Date:  2006-08       Impact factor: 3.352

3.  Differential reversal of drug-induced small bowel paralysis by cerulein and neostigmine.

Authors:  Sonja Fruhwald; Eva Herk; Heinz F Hammer; Peter Holzer; Helfried Metzler
Journal:  Intensive Care Med       Date:  2004-05-18       Impact factor: 17.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.